Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Accounts Payables (2018 - 2026)

10x Genomics' Accounts Payables history spans 8 years, with the latest figure at $12.7 million for Q4 2025.

  • On a quarterly basis, Accounts Payables fell 1.36% to $12.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.7 million, a 1.36% decrease, with the full-year FY2025 number at $12.7 million, down 1.36% from a year prior.
  • Accounts Payables hit $12.7 million in Q4 2025 for 10x Genomics, down from $18.1 million in the prior quarter.
  • Over the last five years, Accounts Payables for TXG hit a ceiling of $29.3 million in Q1 2023 and a floor of $10.1 million in Q1 2025.
  • Historically, Accounts Payables has averaged $19.0 million across 5 years, with a median of $18.5 million in 2023.
  • Biggest five-year swings in Accounts Payables: soared 268.46% in 2021 and later crashed 50.2% in 2025.
  • Tracing TXG's Accounts Payables over 5 years: stood at $17.4 million in 2021, then increased by 24.48% to $21.6 million in 2022, then dropped by 27.14% to $15.7 million in 2023, then fell by 17.98% to $12.9 million in 2024, then decreased by 1.36% to $12.7 million in 2025.
  • Business Quant data shows Accounts Payables for TXG at $12.7 million in Q4 2025, $18.1 million in Q3 2025, and $15.9 million in Q2 2025.